MedTrace Logo

Study to Evaluate the Safety and Efficacy of HLBLS-200 in Patients Requiring Hemostatic Technique

NCT03957356 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-07-22

No results posted yet for this study

Summary

This is a prospective, open-label, exploratory clinical trial designed to investigate the safety and efficacy of HLBLS-200 (an investigational hemostatic agent). The study will recruit approximately 8 subjects.

Conditions

Interventions

DEVICE

HLBLS-200

The amount of HLBLS-200 applied will be determined by the investigator based on the resection area.

Sponsors & Collaborators

  • HLB Cell Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Dongho Choi, MD, Ph.D · Hanyang Univ. Medical Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-19
Primary Completion
2020-03-02
Completion
2020-07-08

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03957356 on ClinicalTrials.gov